Letetresgene autoleucel (Lete-Cel (GSK3377794))

Phase 2Cell therapy

Letetresgene autoleucel (Lete-Cel (GSK3377794)) is one of 17 small molecule programs targeting Synovial Sarcoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Synovial SarcomaActive, not recruiting

Synovial SarcomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

27 competitors in Synovial Sarcoma

#DrugCompanyPhaseTrials

DTIC-Dome

Bayer

Approved

—2

Cytoxan

BBaxter Healthcare Corporation

Phase 3

8 3

Yondelis

AApotex Inc.

Phase 3

1 4

Iressa

AstraZeneca

Phase 2

1 5

Keytruda

Merck & Co.

Phase 2

1 6

Yervoy

Bristol-Myers Squibb

Phase 2

1 7

Herceptin

OOrganon and Co

Phase 2

1 8

Fludara

Sanofi

Phase 1

6 9

Gemzar

Johnson & Johnson

Phase 1

1 10

Cyramza

Eli Lilly

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Solid Tumors

NCT03967223

Phase 2Active, not recruiting

Synovial Sarcoma

NCT06703346

Clinical

Trials by Indication[1]

Solid Tumors1 trial

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

Active, not recruiting·UUSWM CT, LLC·Phase 2·NCT03967223·103 enrolled

Synovial Sarcoma1 trial

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Active, not recruiting·UUSWM CT, LLC·Phase 2·NCT06703346·87 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Letetresgene autoleucel (Lete-Cel (GSK3377794)). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Letetresgene autoleucel (Lete-Cel (GSK3377794)) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Letetresgene autoleucel (Lete-Cel (GSK3377794)). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — USWM CT, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: UUSWM CT, LLC

Letetresgene autoleucel (Lete-Cel (GSK3377794))

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Solid Tumors1 trial

Synovial Sarcoma1 trial

References

Drug Info

Quick Facts

Related News